The complement system is a group of about 35 soluble and cell-surface proteins which interact to recognize, opsonize and clear or kill invading micro-organisms or altered host cells (e.g. apoptotic or necrotic cells). Complement is a major part of the innate immune system. Recognition proteins such as C1q, MBL (mannanbinding lectin) and ficolins bind to targets via charge or sugar arrays. Binding causes activation of a series of serine protease proenzymes, such as C1r, C1s and MASP2 (MBL-associated serine protease 2), which in turn activate the atypical serine proteases factor B and C2, which then activate the major opsonin of the system, C3. Activated C3 binds covalently to targets, and is recognized by receptors on phagocytic cells. Two of the complement proteases, factors D and I, circulate not as proenzymes, but in activated form, and they have no natural inhibitors; their substrates are transient protein complexes (e.g. C3bB and C3bH) which form during complement activation. Factor B and C2 also have no natural inhibitor; they are active only when proteolytically cleaved and bound in an unstable, short-lived complex with C3b or C4b. C1r, C1s and the MASPs, in contrast, are regulated more conventionally by the natural serpin, C1-inhibitor. Complement proteases in general have very narrow specificity, and low substrate turnover with both natural and synthetic substrates. Excessive activation of complement is inflammatory, and causes tissue damage (e.g. in rheumatoid arthritis, or in ischaemia/reperfusion injury). Substances that regulate complement activation are likely to be useful in the regulation of inflammation. Complement activation might potentially be controlled at many different steps. Much attention has been focused on controlling the formation or activity of the protease complexes C3bBb and C4b2a (containing activated factor B and C2 respectively), as these generate the inflammatory peptides C3a and C5a.
Introduction
Complement is a major effector system of innate immunity [1] [2] [3] . There are currently known to be about 25 soluble complement proteins, as well as 10 or more cell-surface complement receptors and regulatory proteins present on a wide range of host cells. Among the soluble complement proteins are four groups of serine proteases. Soluble complement system proteins make up about 5% of the total protein content of human blood plasma. They are also present, at lower concentrations, in other body fluids. The major role of the complement system is to recognize and promote clearance, by phagocytosis, of invading microorganisms and damaged or altered host cells. Complement proteins and activation fragments attached to targets also interact with cells of the adaptive immune system, influencing the host adaptive immune response to micro-organisms or potential autoantigens [4] . Rare hereditary deficiencies in complement proteins predispose to recurrent microbial infection and also to the development of autoimmune conditions, particularly systemic lupus erythematosus, which may be associated with impaired clearance of altered host cells [5] .
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The complement system ( Figure 1 ) recognizes targets by multiple weak interactions between complement recognition proteins and charge or carbohydrate arrays on the target surfaces. The complement system has inbuilt duplication ('redundancy') and there are several overlapping recognition mechanisms. These recognition pathways are called the classical pathway, the lectin pathway, and the alternative pathway.
Complement activation pathways
Recognition by the classical and lectin pathways (Figure 1 ) leads to activation of serine proteases which cleave complement component C2, itself a serine protease, and C4, leading to the formation of the protease complex C4b2a, which cleaves C3 into C3a and C3b. C3b is a central component of the complement system due to its many effector functions [6] . It (and its homologue C4b) binds covalently to complement-activating surfaces via a transesterification reaction between surface hydroxy or amino groups and an internal thiolester in C3 and C4. Surface-bound C3b, and its breakdown product iC3b, act as opsonins for phagocytes. Target-bound C3b and iC3b interact with the complement receptors CR1, CR3 and CR4 to promote adhesion of the target to phagocytic cells. C3b can also bind covalently to the C4b portion of the C3 convertase, C4b2a, to form a C5 convertase (C4b2a3b). Here C3b acts as a binding site for the substrate C5, allowing the protease to cleave C5 as well as The complement system, showing activation by the classical, lectin and alternative pathways. Regulatory/inhibitory proteins are shown in shaded boxes. One positive regulator, properdin, which stabilizes C3bBb, is not shown. FI (etc.), factor I (etc.); MAC, membrane attack complex.
C3. The C5 convertase initiates the assembly of the membrane attack complex, consisting of complement components C5-C9, which forms pores in the lipid bilayers of its targets, potentially causing cell lysis. C3a acts as an anaphylotoxin, mediating inflammatory responses; its homologues C4a and C5a (fragments released during activation of C4 and C5) have similar activity, and C5a is a potent chemotactic factor for neutrophils ( Figure 1) .
The pattern recognition molecule of the classical pathway is C1q, which circulates in blood complexed with two serine protease proenzymes, C1r and C1s, in the C1 complex (C1qr 2 s 2 ) [7] . C1q is a 450 kDa multimeric protein, shaped like a bunch of six tulips. The 'heads' of the tulips each consist of three globular domains through which C1q binds to targets. The 'stems' are collagen triple helices, to which are bound the serine proteases C1r and C1s. Each globular domain of the head region binds weakly to a target charge cluster, so that multiple binding, with engagement of more than one head, is required for high-avidity binding. C1q binds to a wide range of charge/hydrophobicity patterns on target surfaces [8] . C1q also recognizes targets to which the adaptive immune system has already raised an antibody response; it binds to IgG or IgM arrays in immune complexes. Upon binding of C1q to a target, movement of the collagen stems of C1q causes C1r to autoactivate. Activated C1r then cleaves and activates C1s.
The better-known recognition protein of the lectin pathway is MBL (mannan-binding lectin) [9, 10] . MBL is similar in quaternary structure to C1q, in that it is shaped like a bunch of tulips ('sertiform') and has globular heads and collagenous stems. Its globular heads, however, are C-type lectin domains, and they bind not to charge clusters as the C1q heads do, but to neutral sugars (e.g. mannose and N-acetylglucosamine). When MBL was first shown to activate complement, it was thought to act just like C1q, forming a complex with C1r and C1s [9] . This can indeed happen in vitro, but in vivo MBL interacts preferentially with homologues of C1r and C1s, called MASPs (MBL-associated serine proteases) instead. The MASPs were discovered quite recently: the first MASP was extensively characterized by 1994 [11] , MASP2 was characterized in 1997 [12] , and MASP3, an alternatively spliced product from the MASP1 gene, was characterized in 2001 [13, 14] . All three MASPs have the same domain structure as C1r and C1s ( Figure 2 ). MASP1 and MASP3 have identical CUB (complementurchin-bone), EGF (epidermal growth factor) and CCP (complement control protein) domains, but have different SP domains (serine protease domains).
The lectin pathway of complement is initiated through the binding of MBL to carbohydrate structures on a wide range of micro-organisms, including bacteria, viruses, fungi and parasites. MBL also recognizes carbohydrate structures on antibodies, including the common IgG glycosylation variant IgG-G0 [15] and polymeric IgA [16] . MBL is found in serum complexed with the MASPs and a small 19 kDa protein (MAp19). MAp19 is an alternative splicing product of the MASP2 gene, and consists of the N-terminal CUB-EGF domains of MASP2 [14] . Initially it was thought that the first MASP to be discovered (MASP1) was responsible for complement activation, but in fact it is MASP2 that activates complement by cleaving C2 and C4 [17] . MASP2 therefore acts like C1s. The mechanisms for MASP activation have yet to be fully determined, but, upon MBL binding to a target, MASP1 and MASP2 autoactivate independently (unlike C1r and C1s). MASP1 is therefore not equivalent to C1r, and its role remains uncertain. It has been reported to activate C3 directly, but this may be an in vitro artefact. Indirect activation of C3 via another unidentified protease may be a possibility. MASP1 does cleave coagulation factor XIII and fibrinogen [18] , but it is not known whether these are physiologically relevant substrates.
The MASPs also bind to ficolins [9, 19] , another recently discovered group of complement recognition/activation proteins. The ficolins are also similar in quaternary structure to C1q and MBL. They have globular fibrinogen-like domains which make up their head region, and collagenous stalks. Three human ficolins have been discovered to date: Land H-ficolin found in serum, and M-ficolin on the surface of circulating blood monocytes. M-ficolin is not known to be associated with complement activation. All bind GlcNAc via their fibrinogen-like domains, but do not bind mannose.
The alternative pathway is activated by a mechanism quite different from the classical and lectin pathways (Figure 1 ; [20] ). It recognises targets bearing surface clusters of both charge and neutral sugar. It also has both antibody-dependent (IgG immune complexes) and antibody-independent modes of activation. In the alternative pathway, there is continuous spontaneous activation: C3 undergoes hydrolysis of its internal thiolester at a low rate to form C3i [or C3(H 2 O)]. C3i forms a complex with the serine protease factor B, and factor B in the C3iB complex is cleaved by the serine protease factor D to form C3iBb, where Bb is a fragment of factor B containing an SP domain. Bb in the complex cleaves C3 to form C3b plus C3a, and the C3b thus formed binds randomly and covalently to any nearby cell or macromolecular surface. Once deposited on the surface, C3b can bind more factor B, which is cleaved by factor D, forming C3bBb, the alternative pathway C3 convertase. C3bBb is analogous to the other C3 convertase, C4b2a. Once formed, C3bBb turns over more C3, causing more C3b to fix, in clusters, to the target surface, producing strong opsonization. On host surfaces, however, and other 'protected' surfaces, the first-deposited C3b forms a complex with factor H [or its cellsurface homologues CR1, MCP (membrane cofactor protein) and DAF (decay accelerating factor)] instead of factor B, and the C3bH complexes are broken down to iC3b (with release of factor H) by the regulatory serine protease factor I (Figure 2) . If factor H binds before factor B, no amplification of C3b fixation occurs, so the target surface is not opsonized. Factor H recognizes charge features of the surface, so the distinction between surfaces which activate, or do not activate, the alternative pathway is mainly charge distribution, and factors H and I have an important role in controlling complement activation (C3b fixation) by this pathway.
Factor I has a further major downstream role in complement activity. Even when complement activation has occurred, and the target has been opsonized by clusters of fixed C3b, nearly all of the C3b deposited will eventually be broken down by factor I to form iC3b. iC3b is a more effective opsonin than C3b, and is recognized by the complement receptors CR3 and CR4 on phagocytic cells. Once iC3b has formed, it can be broken down to a smaller fragment, C3d or C3dg, which is the major ligand for the receptor CR2, which mediates interactions between innate immunity (complement) and the adaptive immune system (lymphocytes) [4] .
Activities and regulation of complement proteases
The structures and activities of complement proteases have been reviewed in detail [7, 21] . The complement proteases are unusual among plasma proteases in that not all have a natural inhibitor. C1r, C1s and MASPs 1 and 2 (Figure 2 and Table 1 ) are regulated conventionally by interaction with the serpin C1inh (C1-inhibitor). MASP1 and MASP2 can also be inhibited by α 2 -macroglobulin [22] . These serine proteases are similar to many of the coagulation proteases in that they circulate in inactive proenzyme form, are activated by autolysis or proteolysis, and are then inactivated by a serpin. Although in vivo they are active when complexed to C1q, MBL, etc., in vitro they are still active when isolated (i.e. not bound to another protein). As shown in Table 1 , they cleave arginyl bonds in their natural substrates, and a number of synthetic ester and amide substrates have been identified. The three-dimensional structures of the C1r, C1s and MASP2 Table 1 Properties of complement serine proteases MEROPS database identification numbers are used for the complement components which do not have an EC number. Data were obtained from: (i) the MEROPS Peptidase database (merops.sanger.ac.uk), (ii) the BRENDA Enzyme database (www.brenda.uni-koeln.de), (iii) [21] and (iv) [36] . Chemical abbreviations: Tos, p-tosyl; OMe, methyl; Z, N -carboxybenzyloxy; S-Bzl, thiobenzyl; Ac, N -acetyl; Bz, N a -benzoyl; OEt, ethyl; OphNO 2 , p-nitrophenyl. † denotes the cleavage site. ND, not determined; fB, Factor B; fH, Factor H. 
SP domains have been determined by crystallography [23] [24] [25] . MASP3 does not appear to be inhibited by C1inh, and nothing is yet known of its regulation [13] . C2 and factor B ( Figure 2 and Table 1 ), in contrast with the C1r, C1s and MASP group, are active against their natural (protein) substrates only when they are activated by proteolysis and transiently complexed to C4b or C3b. They circulate in an uncleaved form which is inactive in cleaving the natural substrates C3 and C5. They have no natural inhibitor which interacts with their active site, but the activity of the C4b2a and C3bBb complexes is regulated in other ways. Firstly, these Mg 2+ -dependent complexes are unstable, and dissociate with a half-life of a few minutes. Secondly, the complement regulatory proteins factor H, MCP, CR1 and DAF interact with the complexes and promote dissociation. This type of control is called decay acceleration. Once C2a or Bb dissociates, they do not reassociate with C4b or C3b. Thirdly, the C3b or C4b subunits of the complex, when factor H, MCP or CR1 have bound to them, are cleaved by factor I to form iC3b or C4c plus C4d respectively. C2 and factor B both have arginyl specificity in their natural substrates. They have low activity against several synthetic substrates, but for these substrates the uncleaved forms, and the dissociated cleaved forms (C2a and Bb), also have some activity [7, 26, 27] . The three-dimensional structure of a recombinant factor B SP domain has been determined, and it is suggested that the active site of the SP domain within Bb is irreversibly disorientated when Bb dissociates from C3b [28] .
Factor D (Figure 2 and Table 1 ) also has arginyl specificity, and its natural substrate is factor B, but only in the form of the C3b-factor B complex. It has no endogenous inhibitor, and has weak cleavage activity for synthetic arginyl and lysyl substrates. It circulates in active form, and does not require proteolytic activation. Crystallographic studies suggest that the active-site residues are misaligned in the free enzyme, and they are assumed to be brought into a fully active configuration when the natural substrate is bound [28] .
Factor I ( Figure 2 and Table 1 ) again has arginyl specificity, and has no endogenous inhibitor. It circulates in active form, and does not require proteolytic activation. It also attacks its substrates, C4b and C3b, only when they are transiently complexed to one of the complement regulatory proteins factor H, C4bp, CR1 or MCP. Until recently, no synthetic substrates had been found for factor I, but sensitive fluorescence-based assays have now been used to detect cleavage of synthetic substrates (S.A. Tsiftsoglou, unpublished work). It is not established whether, like factor D, factor I requires contact with natural substrate for optimal alignment of the active site.
Inhibition of the complement system
There is considerable interest in therapeutic manipulation of the complement system, to limit tissue damage in a wide range of situations, including ischaemia/reperfusion, xenotransplantation, sepsis and acute and chronic inflammatory conditions (for review, see [2] ). Most effort has been made in controlling C3 and C5 cleavage to diminish the generation of the inflammatory peptides C3a and C5a. The major emphasis has been on the use of recombinant proteins based on the natural regulators, CR1 and MCP, which inhibit the formation of the C3 convertase enzymes. Other prominent work has included the use of antibodies and peptides to inhibit interaction of C5a with its receptor.
Relatively little work has been done on the use of protease inhibitors to control complement, and there are few published studies. The natural serpin C1inh, which regulates C1r, C1s and the MASPs, has been used as a therapeutic for many years to control hereditary angio-oedema (a partial deficiency of C1inh), but it has more recently been shown to be effective in some of the conditions listed above (e.g. ischaemia/reperfusion [29] ). Synthetic protease inhibitors have been developed for complement proteases, but further refinement to enhance selectivity has not been done. A series of peptide inhibitors based on cleavage sequences in serpins were shown to inhibit C1s, factor D and the C3 convertases [30, 31] . Boropeptide inhibitors designed to inhibit thrombin were found to inhibit factor I, but the reported further development of these reagents was aimed at increasing selectivity for thrombin [32] . FUT175 (reviewed in [2] ) inhibits C1s, factor D and the C3 convertases, and is effective in animal models of complement-associated tissue damage. However, FUT175 does inhibit other plasma proteases, and is not sufficiently selective for use in humans. Some further studies on derivatives of FUT175 with complement proteases have been reported [33] . Recent progress in determination of three-dimensional structures and the availability of animal models for complement-mediated tissue damage are likely to accelerate the development of selective inhibitors for complement proteases.
